Supplements

THC/CBD combination reduces RLS severity in patients with multiple sclerosis and idiopathic RLS

In an open-label trial, 2.7 mg THC/2.5 mg CBD significantly improved International Restless Legs Syndrome Rating Scale (IRLS) scores after 1 and 3 months (p < 0.001). Wake after sleep onset (WASO) also significantly decreased (p = 0.015), while sleep latency and sleep efficiency did not change significantly. After 1 year, 66.66% of patients remained on treatment with sustained IRLS improvement (p = 0.000).

1 min read•Updated Jul 7, 2026•0 RCTs•View structured evidence →
Evidence Score34/100
Human RCT☆☆☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.

THC/CBD combination reduces RLS severity in patients with multiple sclerosis and idiopathic RLS The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 34/100 (low).

The Claim

THC/CBD combination reduces RLS severity in patients with multiple sclerosis and idiopathic RLS

This conclusion is most relevant to: 18 patients with RLS (16 with multiple sclerosis, 2 idiopathic); mean age 51.87 years; 55.5% female; median EDSS 2; mean Ashworth score 1 ± 1.19.

What the Research Shows

The conclusion draws on 1 linked study. Highlights from the cited literature:

  • ▸Tetrahydrocannabinol/cannabidiol in the treatment of restless legs syndrome. (Journal of neurology, 2026) —

How It Works

The proposed biological pathway:

  • ▸Cannabinoids inhibit glutamate release in the striatum
  • ▸Reduced glutamate release decreases neuronal hyperexcitability
  • ▸This may alleviate RLS symptoms
  • ▸Result: Reduced RLS severity and improved sleep continuity

Who Might Benefit

Evidence fit by population:

  • ▸18 patients with RLS (16 with multiple sclerosis, 2 idiopathic); mean age 51.87 years; 55.5% female; median EDSS 2; mean Ashworth score 1 ± 1.19

Limitations & Caveats

Important context when interpreting this evidence:

  • ▸Open-label design with no placebo control, limiting causal inference
  • ▸Small sample size (n=18) and majority had comorbid MS, reducing generalizability to idiopathic RLS
  • ▸Short-term follow-up for primary endpoint (3 months); long-term data only for completers

Frequently Asked Questions

What dose of THC/CBD was used in this study?▼

The starting dose was 2.7 mg THC and 2.5 mg CBD, with optional dose titration at week 4.

Did the treatment improve sleep quality?▼

Wake after sleep onset (WASO) significantly decreased, but sleep latency and sleep efficiency did not change significantly.

How long did the benefits last?▼

Improvements in RLS severity were maintained at 1 year in the 66.66% of patients who continued treatment.

Was this study conducted in patients with multiple sclerosis?▼

Yes, 16 out of 18 patients had multiple sclerosis; the remaining 2 had idiopathic RLS.

References

  1. 1.Lillo Triguero L, Pilo de la Fuente B, D&#xed;az D&#xed;az J, L&#xf3;pez Riolobos C, Aladro Benito Y. “Tetrahydrocannabinol/cannabidiol in the treatment of restless legs syndrome..” Journal of neurology, 2026. PMID: 42387200 DOI: 10.1007/s00415-026-13975-y
Disclaimer: This article is auto-generated from structured research data for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.